Breaking AI & Tech News Analyzed

Former England rugby prop Mako Vunipola has confirmed he will be joining Leicester Tigers this summer. The 35-year-old, who has 79 England caps and was part of three British & Irish Lions tours, will reunite with his former England teammate and Leicester head coach, Geoff Parling.Vunipola, currently playing for Vannes in France's ProD2, has opted to extend his career by a year with the Tigers. Parling expressed his excitement about Vunipola's addition, highlighting his experience and skill as valuable assets to the team.“He was hungry for the chance to come back to the Prem and finish in the comp he knows best,” Parling said. The signing is seen as a significant boost to Leicester's pack for the upcoming season.Vunipola spent 13 years of his career at Saracens and will also mentor Leicester's academy youngsters with a view to a possible future coaching career.“It still hasn’t sunk in,” Vunipola said. “It’s something I would never have envisaged but I am honoured to be part of this prestigious club. Tigers are an incredibly well‑supported club and their fans are so passionate about their rugby.”In other rugby news, Exeter Chiefs have announced the signing of Sam Harris from Bath on a two-year deal. Additionally, Leinster and South Africa have been dealt a blow with RG Snyman likely to be out for the rest of the year due to a knee injury.

After clinching the 2026 Asian Cup in Australia, 35‑year‑old defender Saki Kumagai was asked to rank the trophy among the many she has collected over a 17‑year career. She smiled, shook her head and said, “I never compare my titles… this team is from a different generation, so winning this tournament means a lot.” Kumagai is the sole remaining player who lifted the Women’s World Cup in 2011 – the first and only Asian nation to do so. At 21, she scored the decisive penalty in the shoot‑out against the United States, a victory that came just months after the devastating earthquake and tsunami that struck Japan. Today, the squad she captains features teenagers who were toddlers when she made history: forward Maika Hamano was seven, centre‑back Toko Koga five, and top scorer Riko Ueki twelve when Kumagai’s winning penalty was replayed on TV. Kumagai admits she offers little direct advice, but she leads by example, saying, “I try to pass the baton to the next generation to show them how to perform in these moments.” The transition is no accident. In 2005 the Japanese Football Association unveiled a 50‑year vision aimed at expanding participation, climbing FIFA rankings and eventually hosting – and winning – a World Cup. Halfway through that plan, Japan now sits fifth in the FIFA women’s rankings, having added an Olympic silver medal (2021), a second World Cup final (2015), and three Asian Cup titles (2014, 2018, 2026) to its résumé. While the men’s game has progressed more slowly, the women’s side has surged ahead, bolstered by the launch of Asia’s first full‑time professional women’s league in 2021. This structural backbone has produced a squad “propelled by young stars,” as Kumagai notes. Currently playing for the London City Lionesses after spells at Olympique Lyonnais, Bayern Munich and Roma, Kumagai sees herself as a bridge between eras. She hopes her experience will help Japan reclaim the sport’s summit. “We have a lot of good young players,” she says. “They have confidence, they’re gaining experience in Europe, and as an experienced player I want to create a supportive environment for them.”

Mbappé, now 27 and entering his third year as France captain, admits the shift from star player to team caretaker feels "strange" but rewarding. Approaching his 100th cap, the Real Madrid forward says he now prioritises the collective over personal glory.He highlighted that the squad possesses more talent and potential than in 2022, noting that if current form continues he will soon surpass Olivier Giroud’s 57‑goal record, sitting just one goal behind the veteran after a recent strike against Brazil.France’s recent friendlies in the United States underscore that confidence. A 2‑1 win over Brazil saw Dembélé feed Mbappé for the opener, with Hugo Ekitike adding a second, while a 3‑1 victory against Colombia featured first‑time scorer Désiré Doué and a crucial header from Marcus Thuram.The attacking depth is now a hallmark of Didier Deschamps’ side. Alongside Mbappé, Ousmane Dembélé, Michael Olise, Rayan Cherki and Hugo Ekitike rotate fluidly across the front line, offering creativity and unpredictability that render the old “Mbappé‑Giroud foil” obsolete.Defensively, the team showed signs of vulnerability. Misplaced passes and missed tackles were evident, though Maxence Lacroix earned his first cap against Colombia and impressed enough to stake a claim for the World Cup roster.Logistical hiccups also featured in the US tour. Coach Deschamps complained about lengthy airport checks and a mid‑match cooling break that disrupted momentum, describing the three‑minute pause as “not ideal” for teams on the verge of breaking down opponents.Despite these concerns, the camp’s mood remains optimistic. Mbappé believes the squad can “aim high,” while Deschamps continues to fine‑tune his final selection, aware that a wealth of attacking talent alone does not guarantee tournament success.

Palantir’s senior UK representative has warned ministers against yielding to ideologically motivated campaigners as they explore the possibility of terminating a £330 million NHS contract for the company’s Federated Data Platform (FDP).The FDP, an AI‑enabled system intended to unify patient information across the health service, is part of a broader portfolio that includes contracts with the Ministry of Defence, several police forces and the UK’s financial regulator.Louis Mosley, executive vice‑chair of Palantir UK, told The Times that abandoning the deal would jeopardise patient care and hinder progress on the NHS’s most pressing challenges. He highlighted that the platform is projected to generate £150 million in benefits by the end of the decade, delivering a £5 return for every pound spent.According to the Financial Times, senior officials have begun informal discussions about activating a break clause that would allow the FDP’s operation to be transferred to an alternative provider once the system becomes fully operational next year.Palantir, a US‑based data‑analytics firm with ties to the Israeli and US militaries and former U.S. Immigration and Customs Enforcement contracts, has faced sustained opposition from the British Medical Association, which has long criticised the use of its technology in patient‑care settings.Health officials acknowledge the reputational risk, noting that the controversy now extends beyond traditional Labour‑left and Green Party critics. A Department of Health and Social Care spokesperson emphasised that the FDP is designed to improve care coordination, accelerate cancer diagnoses and increase treatment capacity, while maintaining strict data‑security safeguards.Health Secretary Wes Streeting, speaking on the Guardian Politics Weekly podcast, recognised public unease about Palantir’s political affiliations, referencing founder Peter Thiel’s right‑wing connections. He reassured listeners that Palantir does not have direct access to patient data, stating, "The platform is operated by us; Palantir never sees the data."Adoption of Palantir’s technology within the NHS has risen from 118 to 151 organisations since June, though it remains short of the government’s target of 240 organisations by year‑end. Labour backbencher Clive Lewis noted that the issue is becoming a visible concern for voters, reflecting broader anxieties about AI and foreign‑owned infrastructure in critical public services.

The tragic case of Oliver Robinson, a 34-year-old who took his own life in November 2023, has sparked a campaign for stricter controls on private cannabis clinics in the UK. An inquest concluded that Robinson's prescription for medicinal cannabis, issued by Curaleaf Clinic, probably contributed to his death and acted as an obstacle to him receiving proper psychiatric and addiction care. Robinson had been struggling with depression and addiction, and had been treated at the Priory, a private mental health facility. He was initially prescribed medicinal cannabis in May 2022, which initially provided relief but ultimately worsened his condition. The coroner's report highlighted several failings in his care, including the use of an out-of-date GP summary care record and incomplete information in prescribing decisions. Alexander Robinson, Oliver's brother, is now advocating for tighter regulation of private cannabis clinics, including a ban on prescribing to patients with serious mental illness and greater oversight of the rapidly expanding industry. He believes that the current safeguards are not strong enough to protect vulnerable psychiatric patients. The UK government reported about 5,000 NHS prescriptions for licensed cannabis-based medicinal products in 2023, while freedom of information data showed that 659,293 unlicensed cannabis products were privately prescribed in 2024, more than double the number issued in 2023. Critics argue that there is limited evidence that cannabis is an effective treatment for depression and other common mental health conditions. Dr. Pavan Chahl, an expert psychiatrist, told Oliver's inquest that medicinal cannabis should not have been prescribed to someone with a history of severe psychiatric disorder, citing a lack of evidence for efficacy in depression and the risk of worsening symptoms. In response to the campaign, Curaleaf Clinic stated that it would engage constructively with any review or consultation aimed at strengthening patient safety across the sector.

The play 'In the Print' is a tense thriller that dramatizes the 1986-87 stand-off between Rupert Murdoch and Brenda Dean, general secretary of the print union Sogat. The play, written by Robert Khan and Tom Salinsky, explores the Wapping dispute, a pivotal moment in British industrial relations.The play's central plot revolves around Murdoch's attempt to reform newspaper production and the union's resistance to these changes. Murdoch's use of a fake newspaper, The London Post, to justify the relocation of his titles to a deunionized workforce in Wapping is a key element of the play.The production, briskly staged by Josh Roche, features strong performances from the cast, including Alan Cox as Murdoch, Claudia Jolly as Dean, and Russell Bentley as Kelvin MacKenzie, the then editor of the Sun. The play leaves audiences to decide whether Dean was outplayed by Murdoch or if militant trade unionism was already on the decline.The play is part of a series of stage dramatizations of Murdoch's life and career, including James Graham's Ink and Murdoch: The Final Interview. 'In the Print' offers a unique perspective on Murdoch's revolutionary approach to industrial relations and his impact on British conventions.

Unilever, the maker of Marmite and Hellmann's mayonnaise, has agreed to a $44.8 billion deal to combine its food business with US-based McCormick. The deal, which is forecast to result in $600 million of annual cost savings by the end of the third year, will give Unilever majority control of the new company.Under the agreement, McCormick will pay Unilever $15.7 billion in cash and the equivalent of $29.1 billion in shares for most of Unilever's food arm. The new company will combine brands such as Knorr and Pot Noodle with McCormick's condiments and spices, including French's mustard and Cholula hot sauce.Unilever will control 65% of the new spin-off, while McCormick executives will lead the combined company. The deal marks the end of nearly a century of Unilever selling food products in competition against big rivals such as Kraft Heinz, Nestlé, and PepsiCo.The remainder of Unilever, valued at about £100 billion, will focus on beauty, personal care, and home products, repositioning it to compete directly with large household and personal care companies including L'Oréal, Beiersdorf, and Estée Lauder.

The UK's National Health Service (NHS) is facing potential medicine shortages due to supply chain disruptions, with the head of NHS England, Jim Mackey, warning that some medicines could run out in weeks or even days. Mackey cited the country's reliance on imports, with 75% of medicines coming from abroad, as a major concern.Mackey revealed that a team is in place to focus on identifying potential risks in the supply chain, and that the NHS is working to mitigate the impact of any disruptions. He stated that the NHS generally has enough medicine to last a few weeks, but that some products may only have days' worth of supply.The concerns about medicine shortages come amid the ongoing conflict in the Middle East, which has raised worries about cost implications and supply disruption. Experts have noted that pharmacies are seeing disturbing spikes in prices, which can be an early indicator of challenges.The UK government has stated that there are currently no reported medicine shortages as a result of the conflict, but that they are monitoring the situation closely and have established processes in place to manage disruption across the health and social care sector.

Kenyan marathon runner Albert Korir, the 2021 New York City Marathon champion, has been handed a five-year doping ban by the Athletics Integrity Unit (AIU). Korir admitted to using a banned performance-enhancing drug, specifically the synthetic form of erythropoietin (EPO), which stimulates red blood cell production.The ban, which runs from January 8 until January 7, 2031, was reduced from six years due to Korir's early admission and acceptance of the sanction. The 32-year-old athlete tested positive during out-of-competition tests in Kenya in October.Korir has had a notable career, winning the 2021 New York marathon in a time of 2 hours, 8 minutes, and 22 seconds. He also came third in the 2023 New York marathon with a personal best time of 2:06:57. Additionally, he won the Ottawa Marathon in 2019 and 2025.This sanction comes as part of Kenya's ongoing efforts to clean up its image in athletics, following a string of doping scandals. Over 140 Kenyan runners, mainly long-distance athletes, have been sanctioned for drugs offences since the 2016 Rio de Janeiro Olympics. Recently, Kenya handed out its first lifetime ban to marathon runner Beatrice Toroitich and a six-year ban to 10km record holder Rhonex Kipruto in June 2024.